PT  - JOURNAL ARTICLE
AU  - Abul-Husn, Noura S.
AU  - Soper, Emily R.
AU  - Braganza, Giovanna T.
AU  - Rodriguez, Jessica E.
AU  - Zeid, Natasha
AU  - Cullina, Sinead
AU  - Bobo, Dean
AU  - Moscati, Arden
AU  - Merkelson, Amanda
AU  - Loos, Ruth J.F.
AU  - Cho, Judy H.
AU  - Belbin, Gillian M.
AU  - Suckiel, Sabrina A.
AU  - Kenny, Eimear E.
TI  - Implementing genomic screening in diverse populations
AID  - 10.1101/2021.01.04.21249213
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.04.21249213
4099  - http://medrxiv.org/content/early/2021/01/06/2021.01.04.21249213.short
4100  - http://medrxiv.org/content/early/2021/01/06/2021.01.04.21249213.full
AB  - Background Population-based genomic screening has the predicted ability to reduce morbidity and mortality associated with medically actionable conditions. However, much research is needed to develop standards for genomic screening, and to understand the perspectives of people offered this new testing modality. This is particularly true for non-European ancestry populations who are vastly underrepresented in genomic medicine research. Therefore, we implemented a pilot genomic screening program in the BioMe Biobank in New York City, where the majority of participants are of non-European ancestry.Methods We initiated genomic screening for well-established genes associated with hereditary breast and ovarian cancer syndrome (HBOC), Lynch syndrome (LS), and familial hypercholesterolemia (FH). We evaluated and included an additional gene (TTR) associated with hereditary transthyretin amyloidosis (hATTR), which has a common founder variant in African ancestry populations. We evaluated the characteristics of 74 participants who received results associated with these conditions. We also assessed the preferences of 7,461 newly enrolled BioMe participants to receive genomic results.Results In the pilot genomic screening program, 74 consented participants received results related to HBOC (N=26), LS (N=6), FH (N=8), and hATTR (N=34). Thirty-three of 34 (97.1%) participants who received a result related to hATTR were self-reported African/African American (AA) or Hispanic/Latinx (HL), compared to 14 of 40 (35.0%) participants who received a result related to HBOC, LS, or FH. Among 7,461 participants enrolled after the BioMe protocol modification to allow the return of genomic results, 93.4% indicated that they would want to receive results. Younger participants, women, and HL participants were more likely to opt to receive results.Conclusions The addition of TTR to a pilot genomic screening program meant that we returned results to a higher proportion of AA and HL participants, in comparison with genes traditionally included in genomic screening programs in the U.S. We found that the majority of participants in a multi-ethnic biobank are interested in receiving genomic results for medically actionable conditions. These findings increase knowledge about the perspectives of diverse research participants on receiving genomic results, and inform the broader implementation of genomic medicine in underrepresented patient populations.Competing Interest StatementN.S.A-H. was previously employed by Regeneron Pharmaceuticals and has received a speaker honorarium from Genentech. E.E.K. has received speaker honoraria from Illumina and Regeneron Pharmaceuticals. The remaining authors declare no competing interests.Funding StatementThe BioMe Biobank Program is supported by The Andrea and Charles Bronfman Philanthropies and by dedicated funding to the Institute for Personalized Medicine by the Icahn School of Medicine at Mount Sinai. The pilot genomic screening study was supported by dedicated funding to the Institute for Genomic Health by the Icahn School of Medicine at Mount Sinai. The pre-pilot survey study was supported by the Jane Engelberg Memorial Fellowship Student Research Award, provided by the Engelberg Foundation to the National Society of Genetic Counselors, Inc. Whole exome sequencing and genotyping of BioMe was performed in collaboration with the Regeneron Genetics Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BioMe Biobank is an ongoing research biorepository approved by the Icahn School of Medicine at Mount Sinai IRB (protocol number 07-0529). The Icahn School of Medicine at Mount Sinai IRB approved the pre-pilot survey study (protocol number 15-00440), including a waiver of informed consent and a HIPAA waiver of authorization. This research conformed to the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinically confirmed pathogenic, likely pathogenic, and downgraded variants reported in this paper are tabulated in Additional File 1: Table S3. Exome sequencing and genotyping of BioMe Biobank participants was performed in collaboration with the Regeneron Genetics Center. Individual-level data generated via this collaboration are not publicly available due to the terms of the BioMe biospecimen and data access agreement, but may be requested directly from the corresponding author.